Dana dhuwit perusahaan: Klotho Neurosciences Inc (KLTO)

Klotho Neurosciences Inc (KLTO) growth relies on grant funding for preclinical research and future FDA certifications. The size of cash resources demonstrates liquidity for R&D, where the current figure is 0.01. Revenues are planned from the sale of Klotho protein-based therapies. The risk mitigation strategy is based on developing products for the treatment of dementia and Parkinson's disease, targeting the geriatric medicine market.
Ringkesan rincian data analitis anewmeds.com (KLTO)

This metric measures the volume of net liquidity available to cover operational gaps, where the cash level demonstrates actual solvency between reporting periods. For Klotho Neurosciences Inc (KLTO), this reserve is critically important, as the funding for the development of drugs for neurodegenerative diseases depends on the success of clinical trials rather than macroeconomic cycles or GDP phases.